Nonathymulin
Also known as: FTS analog, Thymulin analog, Zn-thymulin analog, ZnT
Source Nonathymulin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Nonathymulin is a synthetic analogue of the thymic peptide hormone thymulin, classified among immunomodulatory and thymic peptides. Research has examined its use as an adjunctive therapy for rheumatoid arthritis, where it showed clinical benefit, and for multiple sclerosis, where it did not demonstrate efficacy. The compound remains in the research stage and is not approved for clinical use.
Mechanism of Action
Nonathymulin is thought to act by modulating T‑cell function, reflecting its origin as a thymic peptide. In rheumatoid arthritis trials, clinical response correlated with changes in T‑cell subset balance measured by monoclonal antibodies and suppressor‑T‑cell assays, suggesting it may restore regulatory T‑cell activity without markedly altering broader immunological parameters.
What the Research Shows
Two double‑blind, placebo‑controlled trials have evaluated nonathymulin. In rheumatoid arthritis, three daily doses (1, 5, 10 mg) were compared; the 5 mg dose yielded the greatest improvement, with 56 % of patients showing clinical benefit versus 17 % on placebo (p < 0.02). The benefit was reflected in global assessments and four objective measures, with minimal adverse effects and no clear shifts in standard immunologic labs, though a link to T‑cell subset imbalance was noted. In a separate trial of 40 patients with evolving, moderately disabled multiple sclerosis, subcutaneous nonathymulin for six months did not produce significant differences in Kurtzke disability scores, ambulation index, or functional scale compared with placebo, and no notable side effects occurred.
Reported Benefits
Evidence from the rheumatoid arthritis trials indicates that a 5 mg daily dose of nonathymulin can produce a statistically significant improvement in clinical status for more than half of treated patients, with a favorable safety profile and minimal reported adverse events. No therapeutic benefit was observed in the multiple sclerosis pilot study.
Limitations of the Evidence
Findings are limited to two small‑scale clinical trials; the rheumatoid arthritis data involve a modest sample and short‑term outcomes, while the multiple sclerosis study showed no efficacy. Dosing beyond 10 mg, long‑term safety, and effects in other autoimmune conditions remain unstudied. The compound has not undergone regulatory evaluation, and immunological mechanisms are only indirectly inferred.
Safety Considerations
Both trials reported minimal adverse effects. In rheumatoid arthritis, side effects were described as minimal, and in multiple sclerosis, no significant side effects were recorded during six months of treatment. No serious safety concerns emerged, but comprehensive safety data are lacking due to the limited size and duration of the studies.
How It Is Administered
The clinical studies administered nonathymulin subcutaneously. The structured data also list intranasal and topical routes, but these have not been evaluated in the cited trials. Formulations used were injectable preparations suitable for subcutaneous injection.
Routes of Administration
Goals & Uses
- NeuroprotectionNeurologyLow
- Immune reconstitution / T-cell modulationImmunologyLow
- Immunosenescence reversalAging / GeroscienceLow
- Hair follicle cycling / alopeciaDermatologyLow
- Anti-inflammatory effectsInflammationLow
Contraindications
- Known hypersensitivity to thymic peptidesAllergic/ImmunologicalHigh
- Active autoimmune diseaseAutoimmunityModerate
Adverse Effects
- Immune dysregulationImmunologicalUnknown
- Injection site reactionsLocalUnknown
Drug Interactions
- Immunosuppressants (e.g., corticosteroids, calcineurin inhibitors)Moderate
- Zinc supplementsLow
Population Constraints
- Patients with active malignancyOncologyRelative
- Pediatric populationAgeRelative
- Pregnant or lactating womenReproductiveRelative
Regulatory Status
- European UnionUnapprovedNot approved by EMA; preclinical research compound
- United StatesUnapprovedResearch compound only; no FDA approval or IND on public record
- United KingdomUnapprovedNot approved by MHRA; research use only
Not approved by FDA, EMA, or any major regulatory agency. Used exclusively in preclinical and early research settings. No IND or clinical trial approvals identified in public databases.
Evidence & Sources
- Journal ArticleModerateAmor B, et al.1987-01-01T00:00:00.000000Z
- Journal ArticleModerateRoullet E, et al.1989-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition has nonathymulin shown benefit for?
In a double‑blind trial, a daily 5 mg subcutaneous dose improved clinical outcomes in rheumatoid arthritis patients, with 56 % responding versus 17 % on placebo.
Has nonathymulin been effective in multiple sclerosis?
No. A six‑month randomized, placebo‑controlled study found no significant difference in disability scores or functional measures between nonathymulin and placebo groups.
What are the known side effects of nonathymulin?
Both trials reported minimal or no significant adverse effects. No serious safety signals were identified, but broader safety data are lacking.
How is nonathymulin administered in research settings?
The published studies used subcutaneous injection. Although intranasal and topical routes are listed, they have not been evaluated in the cited clinical trials.
Is nonathymulin approved for medical use?
No. The compound remains in the research phase and has not received regulatory approval for any indication.
What is Nonathymulin?
Nonathymulin is a synthetic analogue of the thymic peptide hormone thymulin, classified among immunomodulatory and thymic peptides. Research has examined its use as an adjunctive therapy for rheumatoid arthritis, where it showed clinical benefit, and for multiple sclerosis, where it did not demonstrate efficacy. The compound remains in the research stage and is not approved for clinical use.
What is Nonathymulin used for?
Nonathymulin is educationally associated with: Neuroprotection, Immune reconstitution / T-cell modulation, Immunosenescence reversal, Hair follicle cycling / alopecia, Anti-inflammatory effects. Educational only — not medical advice.
How is Nonathymulin administered?
Recorded routes of administration: Intranasal, Subcutaneous, Topical.
What are the potential side effects of Nonathymulin?
Reported adverse effects include: Immune dysregulation, Injection site reactions. This list is not exhaustive — consult a qualified clinician.
Who should avoid Nonathymulin?
Recorded contraindications: Known hypersensitivity to thymic peptides, Active autoimmune disease. Consult a qualified clinician before use.